

CERTIFICATE

Survey of 28 January 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 04 - Factor IX, XI, XII, XIII (224):

Validity 12 months:

Faktor IX

Faktor XI

Faktor XII

Faktor XIII

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr. Martin Spacek, PhD.


Vseobecna fakultni nemocnice v Praze

Centralni hematologicke laboratore ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 01 March 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



CERTIFICATE OF PARTICIPATION

Survey of 28 January 2022

You have participated in the External Quality Assessment with the following analysis


Haemostasis 04 - Factor IX, XI, XII, XIII (224):

Faktor IX
Faktor XI
Faktor XII
Faktor XIII

(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr. Martin Spacek, PhD.
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 01 March 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

